133 related articles for article (PubMed ID: 21240253)
1. Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis.
Dahlman A; Rexhepaj E; Brennan DJ; Gallagher WM; Gaber A; Lindgren A; Jirström K; Bjartell A
Mod Pathol; 2011 May; 24(5):708-19. PubMed ID: 21240253
[TBL] [Abstract][Full Text] [Related]
2. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Dahlman A; Edsjö A; Halldén C; Persson JL; Fine SW; Lilja H; Gerald W; Bjartell A
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):369-75. PubMed ID: 20680031
[TBL] [Abstract][Full Text] [Related]
3. The expression of β-microseminoprotein but not CRISP3 is reduced in ovarian cancer and correlates to survival.
Henriksen R; Lundwall Å; Udby L; Fernlund P
Anticancer Res; 2012 Sep; 32(9):3993-9. PubMed ID: 22993349
[TBL] [Abstract][Full Text] [Related]
4. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
Bjartell AS; Al-Ahmadie H; Serio AM; Eastham JA; Eggener SE; Fine SW; Udby L; Gerald WL; Vickers AJ; Lilja H; Reuter VE; Scardino PT
Clin Cancer Res; 2007 Jul; 13(14):4130-8. PubMed ID: 17634540
[TBL] [Abstract][Full Text] [Related]
5. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
Grupp K; Kohl S; Sirma H; Simon R; Steurer S; Becker A; Adam M; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2013 May; 26(5):733-42. PubMed ID: 23196798
[TBL] [Abstract][Full Text] [Related]
6. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
[TBL] [Abstract][Full Text] [Related]
7. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
Bergström SH; Järemo H; Nilsson M; Adamo HH; Bergh A
Prostate; 2018 Mar; 78(4):257-265. PubMed ID: 29250809
[TBL] [Abstract][Full Text] [Related]
8. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
Sjöblom L; Saramäki O; Annala M; Leinonen K; Nättinen J; Tolonen T; Wahlfors T; Nykter M; Bova GS; Schleutker J; Tammela TL; Lilja H; Visakorpi T
PLoS One; 2016; 11(3):e0150241. PubMed ID: 26939004
[TBL] [Abstract][Full Text] [Related]
9. Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy.
Izumi K; Li Y; Zheng Y; Gordetsky J; Yao JL; Miyamoto H
Hum Pathol; 2012 Nov; 43(11):1991-2000. PubMed ID: 22617231
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases.
Toubaji A; Sutcliffe S; Chaux A; Lecksell K; Hicks J; De Marzo AM; Platz EA; Netto GJ
Hum Pathol; 2012 Nov; 43(11):1852-65. PubMed ID: 22554381
[TBL] [Abstract][Full Text] [Related]
11. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
[TBL] [Abstract][Full Text] [Related]
12. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
Whitaker HC; Warren AY; Eeles R; Kote-Jarai Z; Neal DE
Prostate; 2010 Feb; 70(3):333-40. PubMed ID: 19790236
[TBL] [Abstract][Full Text] [Related]
13. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
[TBL] [Abstract][Full Text] [Related]
14. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3.
Van Eynde A; Litovkin K; Bollen M
Asian J Androl; 2011 Mar; 13(2):205-6. PubMed ID: 21102472
[No Abstract] [Full Text] [Related]
16. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
[TBL] [Abstract][Full Text] [Related]
17. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.
Whitaker HC; Kote-Jarai Z; Ross-Adams H; Warren AY; Burge J; George A; Bancroft E; Jhavar S; Leongamornlert D; Tymrakiewicz M; Saunders E; Page E; Mitra A; Mitchell G; Lindeman GJ; Evans DG; Blanco I; Mercer C; Rubinstein WS; Clowes V; Douglas F; Hodgson S; Walker L; Donaldson A; Izatt L; Dorkins H; Male A; Tucker K; Stapleton A; Lam J; Kirk J; Lilja H; Easton D; ; ; ; Cooper C; Eeles R; Neal DE
PLoS One; 2010 Oct; 5(10):e13363. PubMed ID: 20967219
[TBL] [Abstract][Full Text] [Related]
18. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
19. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
[TBL] [Abstract][Full Text] [Related]
20. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]